🎥 Behind the scenes at EULAR 2026 in London!
While the latest breakthroughs in rheumatology and immunology are being presented at the congress, our team is already hard at work behind the camera. Together with leading international experts, we are presenting the most exciting study results, key congress highlights, and their relevance for clinical practice.
Stay tuned for concise congress summaries, expert perspectives, and the most important take-home messages from EULAR 2026.
📅 Available June 6th 2026, free of charge, on https://t.co/L9MX6UyiTJ – exclusively for healthcare professionals.
#EULAR2026 #EULAR #Rheumatology #Immunology #AutoimmuneDiseases #ClinicalTrials #PrecisionMedicine #MedicalEducation #ImmunologyResearch #high5immunologyTV
All high5oncologyTV ASCO 2026 reports are now available on demand.
🎥 Expert coverage of:
• Breast Cancer
• GU Oncology
• Lung Cancer
✅ Free access
✅ On demand
✅ For healthcare professionals
Watch now:
https://t.co/pbS79Fdlmj
#ASCO26#Oncology#high5oncologyTV
The first reports from our high5oncologyTV ASCO 2026 coverage are now live.
🎥 Expert analysis on:
• Breast Cancer
• GU Cancers
• Lung Cancer
✅ Free
✅ On demand
✅ Directly from Chicago
Watch now and stay up to date with the latest ASCO 2026 data: https://t.co/4PJw1aT9bW
#ASCO26 #Oncology #high5oncologyTV
The OncoAlert🚨 Lung faculty’s TOP 10 abstracts In Thoracic🫁 Oncology for #ASCO26 are here — selected by our leads and finalized through a Delphi voting process with our senior #LungCancer experts across #NSCLC & #SCLC .
A snapshot of what will shape LUNG oncology at #ASCO26 👇
🔹 HARMONI-6 — Ivonescimab + chemo vs tislelizumab + chemo in sqNSCLC (OS, Ph3)
🔹 LIBRETTO-432 — Adjuvant selpercatinib in RET+ NSCLC (EFS, Ph3)
🔹 WU-KONG28 — Sunvozertinib vs chemo in EGFR Ex20ins NSCLC (Ph3)
🔹 OPTITROP-LUNGO5 — Sac-TMT + pembrolizumab in PD-L1+ NSCLC (Ph3)
🔹 TRITON — Tremelimumab/durvalumab/chemo in STK11/KEAP1/KRAS-mut NSCLC
🔹 CROWN 7-year update — Lorlatinib vs crizotinib in ALK+ NSCLC
🔹 LORIN — Neoadjuvant lorlatinib in stage III ALK+ NSCLC
🔹 ACCELERET-LUNG — 1L pralsetinib in RET+ NSCLC
🔹 Silevertinib (BDTX-1535) — Non-classical EGFR-mut NSCLC
🔹 Concurrent CRT + durvalumab in ES-SCLC (Phase III)
Leads
@HHorinouchi@UOzkerim@WeOncologists
Senior Faculty
@GlopesMd@StephenVLiu@peters_solange@CharuAggarwalMD@MartinReck2@christine_lovly
Participating AF
@DrMirallas
Pinging faculty
@bmassutis@UmbertoMalapel1@jillfeldman4@bensolomon1@VanitaNoronha@DrSanjayPopat@DrJNaidoo@Latinamd@JulienMazieres@TerriConneran@BRicciutiMD
The OncoAlert🚨 GU faculty’s TOP 10 abstracts In GU Oncology for #ASCO26 are here — selected by our leads and finalized through a Delphi voting process with our senior GU cancer experts across #ProstateCancer#KidneyCancer#BladderCancer .
A snapshot of what will shape GU oncology at #ASCO26 👇
1️⃣ LBA5007 — TALAPRO-3
Talazoparib + enzalutamide vs placebo + enzalutamide in mCSPC with HRR alterations
2️⃣ LBA1 — PROTEUS
Perioperative apalutamide + ADT vs ADT in high-risk localized/locally advanced prostate cancer (final Phase 3)
3️⃣ 5001 — ENZAMET genomic analysis
Decipher >0.85 to identify benefit from adding docetaxel to ADT + enzalutamide
4️⃣ LBA4511 — KEYNOTE-564 ctDNA
ctDNA dynamics in RCC treated with adjuvant pembrolizumab vs placebo
5️⃣ 4502 — RAMPART
Durvalumab vs active monitoring after resection in RCC (Phase 3 RCT)
6️⃣ 4500 — RADICAL (A031801)
Radium-223 + cabozantinib in RCC with bone metastases
7️⃣ 4507 — EV-302 long-term follow-up
Enfortumab vedotin + pembrolizumab vs chemotherapy in 1L LA/mUC
8️⃣ 4513 — AMBASSADOR (A031501)
HRQoL with adjuvant pembrolizumab vs observation in high-risk MIBC
9️⃣ 4503 — SAKK 06/19
Perioperative intravesical rBCG + chemo-IO strategy in MIBC (primary analysis)
🔟 4510 — KEYNOTE-905
HRQoL with perioperative enfortumab vedotin + pembrolizumab in cisplatin-ineligible MIBC
Leads
@nataliagandur@scocmem@AmandaNizamMD@WeOncologists
Senior Faculty
@montypal@DrDanielHeng@apolo_andrea@DrChoueiri@PGrivasMDPhD@TiansterZhang@neerajaiims@amerseburger@Silke_Gillessen@tompowles1@AndreaNecchi@cdanicas@AOmlin
Pinging
@crisbergerot@HHammersMD@ravikanesvaran@sonpavde@drenriquegrande@scserendipity1@EfstathiouEleni@BraunMDPhD@brian_rini
The 5 Nations Meeting in IBD starts today in Toledo — and the #high5immunologyTV team is live on site to bring you the latest expert insights and highlights from the meeting.
🎥 Full coverage will be available free and on demand starting Monday, May 25. Stay tuned!
#5NationsIBD #IBD #Gastroenterology #InflammatoryBowelDisease #MedicalEducation
Recent weeks have brought important momentum in oncology, including several FDA approvals across different tumor types.
👉 Swipe for a concise overview of current and clinically relevant developments!
#Oncology#Hematology#ProstateCancer#OvarianCancer#MultipleMyeloma
Upgrade your clinical tool kit with the updated high5 breast cancer app: all information from diagnosis, therapy algorithm to management of adverse effects. Developed by leading experts in the field – free download for all HCPs.
Download now for free: https://t.co/hUqpGXdtRy
#BreastCancer #Oncology #EvidenceBasedMedicine #DigitalHealth #oncology #high5md
Missed ASCO GU 2026? We’ve got you covered.
If you couldn’t attend in person, you don’t have to miss out on the key insights: The highlights from ASCO GU 2026 are now available on demand and free of charge on high5oncologyTV.
Concise, clinically relevant, and accessible anytime – exclusively for healthcare professionals.
👉 Register now for free and start watching: https://t.co/r6JE1zCViC
#ASCOGU2026 #GUOncology #Oncology #MedicalEducation #MedEd
ASCO GU 2026 – the latest data in just 100 seconds!
Our on-site experts present the newest insights from ASCO GU 2026 – concise, clinically relevant, and straight to the point.
Stay up to date in genitourinary oncology in no time – on demand and free of charge on high5oncologyTV.
👉 Register now and get the most important results in 100 seconds: https://t.co/r6JE1zCViC
#ASCOGU2026 #GUOncology #Oncology #MedicalEducation #MedEd
⏱️ ASCO GU 2026 is just around the corner!
Stay tuned for exclusive congress highlights and expert discussions – bringing you the latest insights directly from the meeting.
On high5oncologyTV, you’ll be close to the most important new developments in genitourinary oncology.
👉 Register now for free and don’t miss out! https://t.co/r6JE1zCViC
#ASCOGU2026 #GUOncology #Oncology #MedicalEducation #Healthcare #MedEd
ECCO 2026 has come to an end – but the insights and discussions continue.
On our website, you can now explore our full coverage, including exclusive expert videos, key takeaways, and in-depth analyses. Don’t miss the opportunity to catch up on the highlights!
A special thank you to all the experts for the excellent collaboration and for the engaging and lively discussions captured in our videos.
🖥️ Visit our website https://t.co/L9MX6UyiTJ and watch the content now!
#ECCO2026 #MedEd #IBD #ColitisUlcerosa #CrohnsDisease
Couldn’t join ECCO 2026 in person? We’ve got you covered.
Our international experts discussed on how pathway-targeted therapies may reshape treatment strategies, how precision medicine is evolving towards more dynamic, data-driven decision-making, and how earlier intervention concepts and anti-fibrotic strategies could impact long-term disease control.
🔎 Watch the highlights now on https://t.co/L9MX6UyiTJ!
#ECCO2026 #IBD #Immunology #PrecisionMedicine #MedicalEducation
Our content from the ECCO Congress 2026 in Stockholm is now available!
Explore concise summaries, the latest study data and practical expert insights from IBD.
💻 Watch now for free on https://t.co/1B0PQ61RfR
🗓️ Only a few days to go until #ECCO2026!
Look forward to concise 100-second video updates and expert discussions covering the latest advances in IBD management — evidence-based, clinically relevant and to the point.
Register for free at https://t.co/B2U4TlQCrw to stay ahead and make sure you don’t miss any highlights!
#ECCO #IBD #Gastroenterology #Immunology #MedEd
🎓 #ASH2025 – new expert discussions
From indolent and aggressive non-Hodgkin lymphoma and CLL/SLL to treatment strategies in NDMM, r/r MM and the latest advances in CAR T-cell therapy.
👉 Watch now on https://t.co/vv4rOL99G1
#Hematology#Oncology#Lymphoma#MultipleMyeloma #CARTcell
With special thanks to our complete expert panel:
@tobyeyre82, @MJerkeman, @H_Einsele, @hhashmi87, @LipeBrea, @MyelomaOslo, Martin Dreyling, Simone Ferrero, Catherine Thieblemont, Clementine Sarkozy, Maximilian Merz
🔍 Key insights at a glance
The ASH meeting in Orlando is behind us – once again delivering pivotal impulses for hematology:
➡️ exciting new clinical trial data on leukemias, lymphomas & multiple myeloma
➡️ advances in innovative therapeutic approaches
➡️ practice-relevant updates for everyday clinical care
Find in-depth coverage and expert insights on https://t.co/vv4rOL99G1 – free of charge for medical professionals.
🎓 Stay informed and don’t miss what matters!
#ASH2025 #Hematology #Oncology #CongressUpdate #ClinicalHighlights #MedicalEducation